Vitamin D Council needs your help...

Tax-deductible!

Together we can end the illness and disease caused by the worldwide epidemic of vitamin D deficiency.

About Vitamin D Council

Contact Vitamin D Council

Sponsor Vitamin D Council

Follow us on:

Vitamin D Products

(off-site)

These companies donate to the Vitamin D Council.

D-Lite, Renew, & SunSplash UV/Tanning Systems
In-Home ZRT Vitamin D Blood Test Kit
Get Premium Quality Vitamin D Supplements at Great Prices
Vitamin D3 Plus™ from Bio-Tech — contains the cofactors Vitamin D needs to work properly.

Vitamin D Research

back to research menu

Pharmacology

Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis. 2009 Oct;54(4):647–52.
c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D. Leuk Res. 2009 Oct;33(10):1372–8.
Translational research on rapid steroid actions. Steroids. 2009 Sep 24.
Calcitriol (Vectical) for mild to moderate plaque psoriasis. Med Lett Drugs Ther. 2009 Sep 7;51(1320):70–1. Review.
Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am J Physiol Renal Physiol. 2009 Sep;297(3):F791–801.
The full-length calcium-sensing receptor dampens the calcemic response to 1alpha,25(OH)2 vitamin D3 in vivo independently of parathyroid hormone. Am J Physiol Renal Physiol. 2009 Sep;297(3):F720–8.
Microarray analysis of MCF-7 breast cancer cells treated with 1,25-dihydroxyvitamin D3 or a 17-methyl-D-ring analog. Anticancer Res. 2009 Sep;29(9):3585–90.
Antiproliferative and calcemic actions of trans-decalin CD-ring analogs of 1,25-dihydroxyvitamin D3. Anticancer Res. 2009 Sep;29(9):3579–84.
Synthesis and biological activities of 14-epi-MART-10 and 14-epi-MART-11: implications for cancer and osteoporosis treatment. Anticancer Res. 2009 Sep;29(9):3563–9.
Regulation of steroid receptor expression by 1alpha-hydroxyvitamin D5 in hormone-responsive breast cancer cells. Anticancer Res. 2009 Sep;29(9):3555–61.
Themed section: Advances in nutritional pharmacology. Editorial. Br J Pharmacol. 2009 Sep;158(2):393–4.
Role of vitamin D treatment in glucose metabolism in polycystic ovary syndrome. Fertil Steril. 2009 Sep;92(3):1053–8.
The effect of vitamin D2 and vitamin D3 on intestinal calcium absorption in Nigerian children with rickets. J Clin Endocrinol Metab. 2009 Sep;94(9):3314–21.
Promotion of autophagy as a mechanism for radiation sensitization of breast tumor cells. Radiother Oncol. 2009 Sep;92(3):323–8.
1,25(OH)2 vitamin d inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation. 2009 Aug 25;120(8):687–98.
The calcitonin/calcitonin gene related peptide-alpha gene is not required for 1alpha,25-dihydroxyvitamin D3-mediated suppression of experimental autoimmune encephalomyelitis. Arch Biochem Biophys. 2009 Aug 15;488(2):105–8.
Snail2 cooperates with Snail1 in the repression of vitamin D receptor in colon cancer. Carcinogenesis. 2009 Aug;30(8):1459–68.
The vitamin D3 transcriptomic response in skin cells derived from the Atlantic bottlenose dolphin. Dev Comp Immunol. 2009 Aug;33(8):901–12.
The enhanced hypercalcemic response to 20-epi-1,25-dihydroxyvitamin D3 results from a selective and prolonged induction of intestinal calcium-regulating genes. Endocrinology. 2009 Aug;150(8):3448–56.
1alpha,25-dihydroxyvitamin D3 inhibits matrix metalloproteinases induced by Mycobacterium tuberculosis infection. Immunology. 2009 Aug;127(4):539–48.
Cystatin D is a candidate tumor suppressor gene induced by vitamin D in human colon cancer cells. J Clin Invest. 2009 Aug;119(8):2343–58.
Calcitriol 3 microg/g ointment: an effective and safe addition to the armamentarium in topical psoriasis therapy. J Drugs Dermatol. 2009 Aug;8(8 Suppl):s17–22. Review.
Efficacy and safety of topical calcitriol 3 microg/g ointment, a new topical therapy for chronic plaque psoriasis. J Drugs Dermatol. 2009 Aug;8(8 Suppl):s9–16. Review.
The role of topical vitamin D modulators in psoriasis therapy. J Drugs Dermatol. 2009 Aug;8(8 Suppl):s4–8. Review.
Alfacalcidol prevents aromatase inhibitor (Letrozole)-induced bone mineral loss in young growing female rats. J Endocrinol. 2009 Aug;202(2):317–25.
Vitamin D receptor modulates the neoplastic phenotype through antagonistic growth regulatory signals. Mol Carcinog. 2009 Aug;48(8):758–72.
Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol. Bone. 2009 Jul 23.
Effect of vitamin D on blood pressure' a systematic review and meta-analysis. J Hypertens. 2009 Jul 7.
Synthesis of 2alpha-propoxy-1alpha,25-dihydroxyvitamin D3 and comparison of its metabolism by human CYP24A1 and rat CYP24A1. Bioorg Med Chem. 2009 Jul 1;17(13):4296–301.
Immunomodulation by a novel, dissociated Vitamin D analogue. Exp Dermatol. 2009 Jul;18(7):619–27.
New 1alpha,25-dihydroxy-19-norvitamin D(3) compounds constrained in a single A-ring conformation: synthesis of the analogues by ring-closing metathesis route and their biological evaluation. J Med Chem. 2009 Jun 11;52(11):3496–504.
Synergistic induction of gene expression during the differentiation into mature macrophage in human myeloblastic leukemia cells treated with TPA and KH1060. Leuk Res. 2009 Jun;33(6):803–9.
Pivotal Role of Paricalcitol in the Treatment of Calcific Uremic Arteriolopathy in the Presence of a Parathyroid Adenoma. Am J Kidney Dis. 2009 May 27.
Vitamin d. Int J Biochem Cell Biol. 2009 May;41(5):982–5.
Synthesis and anti-inflammatory properties of 1alpha,25-dihydroxy-16-ene-20-cyclopropyl-24-oxo-vitamin D3, a hypocalcemic, stable metabolite of 1alpha,25-dihydroxy-16-ene-20-cyclopropyl-vitamin D3. J Med Chem. 2009 Apr 23;52(8):2204–13.
Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD000227. Review.
Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD000227. Review.
The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate. 2009 Apr 1;69(5):480–93.
Enhancement of 1,25-dihydroxyvitamin D3-mediated suppression of experimental autoimmune encephalomyelitis by calcitonin. Proc Natl Acad Sci U S A. 2009 Mar 12.
Impact of vitamin D receptor activity on experimental autoimmune prostatitis. J Autoimmun. 2009 Mar 6.
Paricalcitol reduces basal and lipopolysaccharide-induced (LPS) TNF-alpha and IL-8 production by human peripheral blood mononuclear cells. Int Urol Nephrol. 2009 Mar 4.
Vitamin D metabolism and vitamin D traditional and nontraditional, target organs: implications for kidney patients. J Ren Care. 2009 Mar;35 Suppl 1:39–44.
The efficacy and safety of calcitriol and/or Caltrate D in elderly Chinese women with low bone mass. Acta Pharmacol Sin. 2009 Mar;30(3):372–8.
Direct upregulation of parathyroid calcium-sensing receptor and vitamin D receptor by calcimimetics in uremic rats. Am J Physiol Renal Physiol. 2009 Mar;296(3):F605–13.
Calcium metabolism in the early posttransplantation period. Clin J Am Soc Nephrol. 2009 Mar;4(3):665–72.
Absence of adynamic bone disease in African- Americans with CKD Stage 5 after 3 years of vitamin D therapy guided by iPTH and the PTH-(1-84)/N-terminally truncated PTH fragments ratio. Clin Nephrol. 2009 Mar;71(3):267–75.
Low serum 25 (OH) vitamin D levels ( Transl Res. 2009 Jan;153(1):11–6.
Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift? Nat Clin Pract Nephrol. 2009 Jan;5(1):24–33.
Nonclassic actions of vitamin D. J Clin Endocrinol Metab. 2009 Jan;94(1):26–34.
25-Hydroxyvitamin D(3) is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture. Breast Cancer Res Treat. 2009 Jan;113(1):31–41.
Vitamin D and the vasculature: can we teach an old drug new tricks? Expert Opin Ther Targets. 2009 Jan;13(1):29–38.
Induction of tolerogenic dendritic cells by vitamin d receptor agonists. Handb Exp Pharmacol. 2009;(188):251–73.
Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int. 2008 Dec;74(11):1394–402.
A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet. Eur J Endocrinol. 2008 Dec;159 Suppl 1:S101–5.
Vitamin D analogs: Therapeutic applications and mechanisms for selectivity. Mol Aspects Med. 2008 Dec;29(6):433–52.
Novel Gemini vitamin D(3) analogs have potent antitumor activity. J Steroid Biochem Mol Biol. 2008 Nov;112(1–3):151–6.
Superagonistic fluorinated vitamin d(3) analogs stabilize helix 12 of the vitamin d receptor. Chem Biol. 2008 Oct 20;15(10):1029–34.
Vitamin D: a rapid review. Urol Nurs. 2008 Oct;28(5):343–9, 384; quiz 350.
Vanadium and 1, 25 (OH)2 vitamin D3 combination in inhibitions of 1,2, dimethylhydrazine-induced rat colon carcinogenesis. Biochim Biophys Acta. 2008 Oct;1780(10):1106–14.
Toxicity and antitumor activity of the vitamin D analogs PRI-1906 and PRI-1907 in combined treatment with cyclophosphamide in a mouse mammary cancer model. Cancer Chemother Pharmacol. 2008 Oct;62(5):787–97.
Skeletal effects of systemic and topical corticosteroids. Curr Drug Saf. 2008 Sep;3(3):190–3. Review.
Evaluation and correction of low vitamin D status. Curr Osteoporos Rep. 2008 Sep;6(3):95–9. Review.
Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1535–41.
Prospective study of combined treatment with interferon-alpha and active vitamin D3 for Japanese patients with metastatic renal cell carcinoma. Int J Urol. 2008 Sep;15(9):794–9.
Comparison of Daily, Weekly, and Monthly Vitamin D3 in Ethanol Dosing Protocols for Two Months in Elderly Hip Fracture Patients. J Clin Endocrinol Metab. 2008 Sep;93(9):3430–5.
Vitamin D(2) supplementation induces the development of aortic stenosis in rabbits: Interactions with endothelial function and thioredoxin-interacting protein. Eur J Pharmacol. 2008 Aug 20;590(1–3):290–6.
Identification of the functional vitamin D response elements in the human MDR1 gene. Biochem Pharmacol. 2008 Aug 15;76(4):531–42.
25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008 Aug 11;168(15):1629–37.
Novel vitamin D3 analogs, 1alpha, 25(OH)2D(3)-26, 23-lactam (DLAMs), antagonize bone resorption via suppressing RANKL expression in osteoblasts. Biochem Biophys Res Commun. 2008 Aug 1;372(3):434–9.
Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J Clin Endocrinol Metab. 2008 Aug;93(8):3015–20.
Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol. 2008 Aug;19(8):1509–19.
Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics. 2008 Aug;122(2):398–417. Review.
The noncalciotropic actions of vitamin D: recent clinical developments. Curr Opin Nephrol Hypertens. 2008 Jul;17(4):408–15. Review.
Vitamin D derivatives acutely reduce endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol. 2008 Jul;295(1):H289–96.
Secondary osteoporosis in long-term bedridden patients with cerebral palsy. Pediatr Int. 2008 Jun;50(3):269–75.
Mineral metabolism and bone abnormalities in children with chronic renal failure. Rev Endocr Metab Disord. 2008 Jun;9(2):131–7. Review.
Insulin resistance, renal injury, renal 1-alpha hydroxylase, and bone homeostasis in aged obese rats. Arch Med Res. 2008 May;39(4):380–7.
Vitamin D insufficiency underlies unexpected hypocalcemia following high dose glucocorticoid therapy. Bone. 2008 Jan;42(1):226–8.
Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis). Nefrologia. 2008;28 Suppl 3:67–78. In Spanish.
Vitamin D receptor agonists in the treatment of autoimmune diseases: selective targeting of myeloid but not plasmacytoid dendritic cells. J Bone Miner Res. 2007 Dec;22 Suppl 2:V69–73. Review.
The antitumor effect of lowered doses of cytostatics combined with new analogs of vitamin D in mice. Anticancer Res. 2007 Sep–Oct;27(5A):3387–98.
Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis. 2007 Jul;50(1):59–68.
What is new in vitamin D: 2006–2007. Curr Opin Rheumatol. 2007 Jul;19(4):383–8.
Phenobarbital suppresses vitamin D3 25-hydroxylase expression: a potential new mechanism for drug-induced osteomalacia. Biochem Biophys Res Commun. 2007 Jun 8;357(3):603–7.
Vitamin d and its role in cancer and immunity: a prescription for sunlight. Nutr Clin Pract. 2007 Jun;22(3):305–22. Review.
Efficacy of daily and monthly high-dose calciferol in vitamin D-deficient nulliparous and lactating women. Am J Clin Nutr. 2007 Jun;85(6):1565–71.
Effect of 2-Methylene-19-nor-(20S)-1alpha-Hydroxy- Bishomopregnacalciferol (2MbisP), an Analog of Vitamin D, on Secondary Hyperparathyroidism. J Bone Miner Res. 2007 May;22(5):686–94.
Effects of atorvastatin on vitamin d levels in patients with acute ischemic heart disease. Am J Cardiol. 2007 Apr 1;99(7):903–5.
Antitumor properties of diastereomeric and geometric analogs of vitamin D3. Anticancer Drugs. 2007 Apr;18(4):447–57.
Successful treatment of refractory warts with topical vitamin D(3) derivative (maxacalcitol, 1alpha, 25-dihydroxy-22-oxacalcitriol) in 17 patients. J Dermatol. 2007 Apr;34 (4):264–6.
Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol. 2007 Apr;59(5):581–7.
Vitamin D analogs for secondary hyperparathyroidism: What does the future hold? J Steroid Biochem Mol Biol. 2007 Mar;103(3–5):578–83.
Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem Mol Biol. 2007 Mar;103(3–5):689–93.
Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int. 2007 Mar;27(5):425–34.
Difluoromethyl analogs of the natural hormone 1alpha,25-dihydroxyvitamin D(3): Design, synthesis, and preliminary biological evaluation. J Steroid Biochem Mol Biol. 2007 Mar;103(3–5):213–21.
Structure-activity relationships of 19-norvitamin D analogs having a fluoroethylidene group at the C-2 position. Bioorg Med Chem. 2007 Feb 1;15(3):1475–82.
Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):134–44. Review.
New 19-nor-(20S)-1alpha,25-dihydroxyvitamin D(3) analogs strongly stimulate osteoclast formation both in vivo and in vitro. Bone. 2007 Feb;40(2):293–304.
ED-71, a novel vitamin D analog, promotes bone formation and angiogenesis and inhibits bone resorption after bone marrow ablation. Bone. 2007 Feb;40(2):281–292.
Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007;27(1):36–43.
The effect of combined treatment on head and neck human cancer cell lines with novel analogs of calcitriol and cytostatics. Oncol Res. 2007;16(11):517–25.
Synthesis and evaluation of a 3-position diastereomer of 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D(3) (ED-71). Bioorg Med Chem. 2006 Dec 1;14(23):8050–6.
Comparison of the efficacy of calcipotriol and maxacalcitol in combination with narrow-band ultraviolet B therapy for the treatment of psoriasis vulgaris. Photodermatol Photoimmunol Photomed. 2006 Oct;22(5):262–4.
Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. Pediatr Nephrol. 2006 Oct;21(10):1434–9.
Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59 degrees N. AIDS. 2006 Sep 11;20(14):1906–1907.
Antiepileptic drugs and bone metabolism. Nutr Metab (Lond). 2006 Sep 6;3(1):36
Recent studies on vitamin D metabolizing enzymes. Clin Calcium. 2006 Jul;16(7):1129–35. Review.
Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial. Mov Disord. 2006 Jul;21(7):924–9.
Synthesis of putative metabolites of 1alpha,25-dihydroxy-2beta-(3-hydroxy propoxy)vitamin D(3) (ED-71). Steroids. 2006 Jul;71(7):529–40.
Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. J Pharmacol Exp Ther. 2006 Jul;318(1):90–8.
New 2-alkylidene 1alpha,25-dihydroxy-19-norvitamin D3 analogues of high intestinal activity: synthesis and biological evaluation of 2-(3'-alkoxypropylidene) and 2-(3'-hydroxypropylidene) derivatives. J Med Chem. 2006 May 18;49(10):2909–20.
Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer. 2006 May 15;106(10):2136–42.
Vitamin D2 dose required to rapidly increase 25OHD levels in osteoporotic women. Eur J Clin Nutr. 2006 May;60(5):681–7.
Vitamin D receptor is a novel drug target for ovarian cancer treatment. Curr Cancer Drug Targets. 2006 May;6(3):229–44. Review.
Practical synthesis and evaluation of the biological activities of 1alpha,25-dihydroxy vitamin D3 antagonists, 1alpha,25-dihydroxy vitamin D3-26,23-lactams. Designed on the basis of the helix 12-folding inhibition hypothesis. J Med Chem. 2006 Apr 20;49(8):2398–406.
Oral treatment with a vitamin D3 analogue (BXL628) has anti-inflammatory effects in rodent model of interstitial cystitis. BJU International Volume 97 Page 617—March 2006.
Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis. Rheumatol Int. 2006 Mar;26(5):445–53.
Pharmacological treatment to augment hole board habituation in prenatal Vitamin D-deficient rats. Behav Brain Res. 2006 Jan 6;166(1):177–83.
Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int. 2006 Jan;69(1):33–43. Review.
Vitamin D analogs as anti-carcinogenic agents. Anticancer Agents Med Chem. 2006 Jan;6(1):53–71. Review.
New horizons of ED-71 (vitamin D analog) Clin Calcium. 2006 Jan;16(1):131–5. In Japanese.
Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8680–5.
Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clin Cancer Res. 2005 Nov 1;11(21):7794–9.
Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int. 2005 Nov;68(5):1973–81. Review.
Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol. 2005 Oct;97(1–2):93–101. Review.
Colon cancer and solar ultraviolet B radiation and prevention and treatment of colon cancer in mice with vitamin D and its Gemini analogs. J Steroid Biochem Mol Biol. 2005 Oct;97(1–2):111–20.
Inhibitory effect of 22-oxa-1,25-dihydroxyvitamin D3, maxacalcitol, on the proliferation of pancreatic cancer cell lines. J Steroid Biochem Mol Biol. 2005 Oct;97(1–2):173–7.
Skin cancer prevention: a possible role of 1,25dihydroxyvitamin D3 and its analogs. J Steroid Biochem Mol Biol. 2005 Oct;97(1–2):137–43.
Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis. J Rheumatol Suppl. 2005 Sep;76:33–40.
Alfacalcidol versus plain vitamin D in inflammation induced bone loss. J Rheumatol Suppl. 2005 Sep;76:26–32. Review.
High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study. J Urol. 2005 Sep;174(3):888–92.
The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial. Arch Intern Med. 2005 Aug 8–22;165(15):1737–42.
Antioxidative effect of vitamin D3 on zinc-induced oxidative stress in CNS. Ann N Y Acad Sci. 2005 Aug;1053:319–29.
The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures. J Musculoskelet Neuronal Interact. 2005 Jul–Sep;5(3):273–84. Review.
The role of vitamin D in vascular calcification in chronic kidney disease. Semin Dial. 2005 Jul–Aug;18(4):307–14. Review.
Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD000227. Review.
Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int. 2005 Mar;76(3):176–86.
1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts. J Bone Miner Res. 2005 Feb;20(2):305–17.
Lack of effect of calcium intake on the 25-hydroxyvitamin d response to oral vitamin D3. J Clin Endocrinol Metab. 2005 Feb;90(2):707–11.
Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse. Endocrinology. 2005 Feb;146(2):825–34.
Metabolism of vitamin D3 by cytochromes P450. Front Biosci. 2005 Jan 1;10:119–34. Review.
Menatetrenone and vitamin D2 with calcium supplements prevent nonvertebral fracture in elderly women with Alzheimer's disease. Bone. 2005 Jan;36(1):61–8.
A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. JNNP 2005;76:1294–1296.
Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells. Clin Cancer Res. 2004 Dec 1;10(23):8018–27.
Toxicity and antineoplastic effect of (24R)-1,24-dihydroxyvitamin D3 (PRI-2191). Steroids. 2004 Sep;69(10):629–35.
Vitamin D2 Is Much Less Effective than Vitamin D3 in Humans Journal of Clinical Endocrinology & Metabolism 2004 Aug Vol. 89, No. 11 5387–5391.
1,25-Dihydroxyvitamin D and three low-calcemic analogs decrease UV-induced DNA damage via the rapid response pathway. J Steroid Biochem Mol Biol. 2004 May;89–90(1–5):567–70.
2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 potently stimulates gene-specific DNA binding of the vitamin D receptor in osteoblasts. J Biol Chem. 2003 Aug 22;278(34):31756–65.
Metabolism of 26,26,26,27,27,27-F6-1alpha,25-dihydroxyvitamin D3 by CYP24: species-based difference between humans and rats. Biochem Pharmacol. 2003 Jun 15;65(12):1957–65.
Zinc–induced apoptosis in substantia nigra of rat brain: neuroprotection by vitamin D3. Free Radic Biol Med. 2003 Jun 1;34(11):1416–25.
New vitamin D analogs. Kidney Int Suppl. 2003 Jun;(85):S83–7. Review.
Vitamin D receptor as a drug discovery target. Mini Rev Med Chem. 2003 May;3(3):193–204. Review.
Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes. Ann N Y Acad Sci. 2003 Apr;987:258–61. Review.
Rationale for active vitamin D and analogs in the treatment of osteoporosis. J Cell Biochem. 2003 Feb 1;88(2):381–6. Review.
Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res. 2003;164:239–46.
Vitamin D analogs and breast cancer. Recent Results Cancer Res. 2003;164:333–48. Review.
Evaluation of vitamin D analogs as therapeutic agents for prostate cancer. Recent Results Cancer Res. 2003;164:273–88.
Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther. 2002 Dec;72(6):648–59.
Renal failure and vitamin D. Clin Calcium. 2002 Jun;12(6):711–23. In Japanese.
Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases. Int Immunopharmacol. 2002 Jun;2(7):1017–28. Review.
New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab. 2002 Apr;13(3):100–5. Review.
Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer. 2002 Mar;9(1):45–59. Review.
Vitamin D analogs: new therapeutic agents for secondary hyperparathyroidism. Treat Endocrinol. 2002;1(5):313–27. Review.
Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant. 2002;17 Suppl 10:10–9. Review.
Vitamin D analogs for the treatment of secondary hyperparathyroidism. Blood Purif. 2002;20(1):109–12. Review.
Vitamin D analogues for the management of secondary hyperparathyroidism. Am J Kidney Dis. 2001 Nov;38(5 Suppl 5):S34–40. Review.
Enzymatic studies on the key enzymes of vitamin D metabolism; 1 alpha-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24). Biotechnol Annu Rev. 2001;7:179–94. Review.
Cancer chemoprevention using natural vitamin D and synthetic analogs. Annu Rev Pharmacol Toxicol. 2001;41:421–42. Review.
Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev. 2001;(1):CD000227. Review.
Prevention of N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats by 1alpha-hydroxyvitamin D(5). J Natl Cancer Inst. 2000 Nov 15;92(22):1836–40.
Vitamin D deficiency among immigrants. Ugeskr Laeger. 2000 Nov 13;162(46):6196–9. Review in Danish.
Dual metabolic pathway of 25-hydroxyvitamin D3 catalyzed by human CYP24. Eur J Biochem. 2000 Oct;267(20):6158–65.
Conceptually new deltanoids (vitamin D analogs) inhibit multistage skin tumorigenesis. Carcinogenesis. 2000 Jul;21(7):1341–5.
24,25-dihydroxyvitamin D3 in combination with 1,25-dihydroxyvitamin D3 ameliorates renal osteodystrophy in rats with chronic renal failure. Clin Nephrol. 2000 May;53(5):362–71.
Prevention of vitamin D deficiency in adolescents and pre-adolescents. An interventional multicenter study on the biological effect of repeated doses of 100,000 IU of vitamin D3. Arch Pediatr. 2000 Feb;7(2):148–53.
Regulation of renal calbindin-D28K. Pharmacol Toxicol. 2000;87 Suppl 3:5–30. Review.
1,25-Dihydroxyvitamin D3—a hormone with immunomodulatory properties. Z Rheumatol. 2000;59 Suppl 1:24–7. Review.
Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev. 2000;(2):CD000227. Review.
Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium. Calcif Tissue Int. 1999 Oct;65(4):337–40.
Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy. Calcif Tissue Int. 1999 Oct;65(4):295–306. Review.
Vitamin D analogs: perspectives for treatment. Miner Electrolyte Metab. 1999 Jul–Dec;25(4–6):337–41. Review.
20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines. Anticancer Res. 1999 May–Jun;19(3A):1689–97.
New 1alpha,25-dihydroxy-19-norvitamin D3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues. J Med Chem. 1998 Nov 5;41(23):4662–74.
Evidence that vitamin D3 increases serum 25-hydroxy vitamin D more efficiently than does vitamin D2. Am J Clin Nutr. 1998 Oct;68(4):854–8.
19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells. Cancer Res. 1998 Aug 1;58(15):3370–5.
19-Nor-1-alpha-25-dihydroxy vitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol. 1998 Aug;9(8):1427–32.
Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men. Osteoporos Int. 1998;8(3):222–30.
Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects. J Cell Biochem. 1997 Sep 1;66(3):413–25.
Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol. 1997 Aug;19(1):15–27.
Vitamin D metabolism in human colon adenocarcinoma-derived Caco-2 cells: expression of 25-hydroxyvitamin D3-1alpha-hydroxylase activity and regulation of side-chain metabolism. J Steroid Biochem Mol Biol. 1997 May;62(1):21–8.
Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5. J Natl Cancer Inst. 1997 Feb 5;89(3):212–8.
Fortified milk and supplements of oral vitamin D. Comparison of the effect of two doses of vitamin D (500 and 1,000 UI/d) during the first trimester of life. Arch Pediatr. 1997 Feb;4(2):126–32. In French.
Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 8. Vitamin D metabolites and analogs in the treatment of osteoporosis. CMAJ. 1996 Oct 1;155(7):955–61. Review.
1,25-Dihydroxyvitamin D3 as a natural regulator of human immune functions. J Investig Dermatol Symp Proc. 1996 Apr;1(1):68–71. Review.
Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol. 1996 Mar;7(3):488–96.
Characterization of a vitamin D3-resistant MCF-7 cell line. Endocrinology. 1996 Feb;137(2):400–9.
Vitamin D3 analogs and salmon calcitonin partially reverse the development of renal osteodystrophy in rats. Calcif Tissue Int. 1995 Nov;57(5):385–91.
Effect of three levels of vitamin D intake in preterm infants receiving high mineral-containing milk. J Pediatr Gastroenterol Nutr. 1995 Aug;21(2):182–9.
Potent vitamin D3 analogs: their abilities to enhance transactivation and to bind to the vitamin D3 response element. Leuk Res. 1995 Mar;19(3):147–58.
Vitamin D and pubertal maturation. Value and tolerance of vitamin D supplementation during the winter season. Arch Pediatr. 1995 Mar;2(3):221–6. In French.
Vitamin D3 analogs: effect on leukemic clonal growth and differentiation, and on serum calcium levels. Leuk Res. 1995 Jan;19(1):65–72.
Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology. 1995 Jan;136(1):20–6.
Immune modulation by vitamin D analogs in the prevention of autoimmune diseases. Verh K Acad Geneeskd Belg. 1995;57(5):371–85; discussion 385–7. In Dutch.
1,25(OH)2-16ene-vitamin D3 is a potent antileukemic agent with low potential to cause hypercalcemia. Leuk Res. 1994 Jun;18(6):453–63.
Selective biological response by target organs (intestine, kidney, and bone) to 1,25-dihydroxyvitamin D3 and two analogues. Cancer Res. 1993 Sep 1;53(17):3935–42.
Mineral and vitamin D adequacy in infants fed human milk or formula between 6 and 12 months of age. J Pediatr. 1990 Aug;117(2 Pt 2):S134–42. Review.
Synthesis and biological activity of novel vitamin D analogues: 24,24-difluoro-25-hydroxy-26,27-dimethylvitamin D3 and 24,24-difluoro-1 alpha,25-dihydroxy-26,27-dimethylvitamin D3. J Med Chem. 1990 Feb;33(2):480–90.
Effects of ergocalciferol supplementation on the concentration of vitamin D and its metabolites in human milk. J Nutr. 1989 Nov;119(11):1639–46.
Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absorption or bone mobilization. Blood. 1989 Jul;74(1):82–93.
Reduced deposition of aluminium in trabecular bone of uraemic rats treated with dihydroxylated vitamin D metabolites. Nephrol Dial Transplant. 1989;4(11):957–65.
Effects of 1 alpha,25- and 24R,25-dihydroxyvitamin D3 on aluminum-induced rickets in growing uremic rats. J Bone Miner Res. 1987 Dec;2(6):533–45.
Main endocrine modulators of vitamin D hydroxylases in human pathophysiology. J Steroid Biochem. 1987;27(4–6):815–24. Review.
The influence of 1 alpha,25- and 24(R),25-dihydroxyvitamin D3 on bone constituents during early mineralization in the rat. Bone Miner. 1986 Oct;1(5):383–96.
The difference of biological activity among four diastereoisomers of 1 alpha,25-dihydroxycholecalciferol-26,23-lactone. J Steroid Biochem. 1986 Oct;25(4):505–10.
1,25-Dihydroxyvitamin D3 treatment results in increased choline acetyltransferase activity in specific brain nuclei. Endocrinology. 1986 Apr;118(4):1433–9.
Studies on the hydroxylation of vitamin D in man. Ann Med Interne (Paris). 1986;137(3):206–8.
Metabolism of vitamin D in patients with primary biliary cirrhosis and alcoholic liver disease. Clin Sci (Lond). 1985 Nov;69(5):561–70.
Vitamin D absorption in healthy subjects and in patients with intestinal malabsorption syndromes. Am J Clin Nutr. 1985 Oct;42(4):644–9.
Long-term treatment of postmenopausal osteoporosis with active vitamin D3, 1-alpha-hydroxycholecalciferol (1 alpha-OHD3) and 1,24 Dihydroxycholecalciferol (1,24(OH)2D3). Endocrinol Jpn. 1985 Apr;32(2):305–15.
Vitamin D metabolism and osteomalacia in cystic fibrosis. Gastroenterology. 1985 Mar;88(3):808–13.
Anticonvulsant drug therapy in human pregnancy: effects on serum concentrations of vitamin D metabolites in maternal and cord blood. Am J Obstet Gynecol. 1984 Oct 1;150(3):254–8.
26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3: a highly potent, long-lasting analog of 1,25-dihydroxyvitamin D3. Arch Biochem Biophys. 1984 Feb 15;229(1):348–54.
Serum dihydroxyvitamin D metabolite concentrations in patients on chronic anticonvulsant drug therapy: response to pharmacologic doses of vitamin D2. Metab Bone Dis Relat Res. 1983–1984;5(1):1–6.
Metabolism and binding properties of 24,24-difluoro-25-hydroxyvitamin D3. Arch Biochem Biophys. 1983 Sep;225(2):649–55.
Variation of 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 levels in human plasma obtained from 758 Japanese healthy subjects. J Nutr Sci Vitaminol (Tokyo). 1983 Jun;29(3):271–81.
23-Keto-25-hydroxyvitamin D3: a vitamin D3 metabolite with high affinity for the 1,25-dihydroxyvitamin D specific cytosol receptor. Biochemistry. 1983 Jan 18;22(2):245–50.
Serum vitamin D metabolites in epileptic patients treated with 2 different anti-convulsants. Acta Neurol Scand. 1982 Sep;66(3):335–41.
Vitamin D metabolism in hypoparathyroidism. J Clin Endocrinol Metab. 1980 Sep;51(3):606–10.
Advances in vitamin D metabolism as they pertain to chronic renal disease. Am J Clin Nutr. 1976 Nov;29(11):1283–99.
Radioligand receptor assay for 25-hydroxyvitamin D2/D3 and 1 alpha, 25-dihydroxyvitamin D2/D3. J Clin Invest. 1976 Jul;58(1):61–70.
Vitamin D: the discovery of its metabolites and their therapeutic applications. Pediatrics. 1976 May;57(5):729–41. Review.
The kidney as an endocrine organ involved in the function of vitamin D. Am J Med. 1975 Jan;58(1):39–47. Review.
New developments in pharmacology of vitamin D. Med Lett Drugs Ther. 1974 Feb 1;16(3):15–6.
Synthetic analogs of 1alpha,25-dihydroxyvitamin D3 and their biological activity. Vitam Horm. 1974;32:385–406. Review.
Gas chromatographic determination of vitamin D in cod liver oil, pharmaceuticals and veterinary preparations. Int J Vitam Nutr Res. 1973;43(3):271–82.

back to research menu

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Unless otherwise expressly stated, all site content licensed under a Creative Commons License.